Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Rifaximin in Minimal Hepatic Encephalopathy

This study has been completed.
Valeant Pharmaceuticals International, Inc.
Information provided by (Responsible Party):
Jasmohan Bajaj, Hunter Holmes Mcguire Veteran Affairs Medical Center Identifier:
First received: February 16, 2010
Last updated: December 10, 2012
Last verified: December 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):